MMMasaru Matsui

Masaru Matsui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaru Matsui has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Body Shape Index and Risk of Kidney Function Decline in Older Adults with CKD

    by Takaaki Kosugi, Masahiro Eriguchi, Hisako Yoshida, Hiroyuki Tamaki, Takayuki Uemura, Hikari Tasaki, Riri Furuyama, Masatoshi Nishimoto, Katsuhiko Morimoto, Masaru Matsui, et al.

    Background: A Body Shape Index has recently emerged as a useful obesity marker for predicting adverse events. Although its usefulness has been reported even in older adults, who tend to exhibit the obesity paradox, little evidence is available regarding the association between A Body Shape Index and kidney outcomes. This study aimed to investigate the associations between A Body Shape Index or body mass index (BMI) and kidney outcomes in older adults with CKD. Methods: This nationwide longitudinal observational study included individuals aged 65–74 years with CKD who underwent annual health checkups between 2008 and 2014. Exposures of interest were A Body Shape Index and BMI, and the primary outcome was a 40% decline in estimated glomerular filtration rate (eGFR). The associations between quartiles (Q1–Q4) of A Body Shape Index and BMI and a 40% decline in eGFR were assessed using Cox regression analysis for each sex. Restricted cubic spline analysis was performed to investigate nonlinear associations. The eGFR trajectory across A Body Shape Index categories was evaluated using a mixed-effects model. Results: Among 31,292 men and 23,167 women with CKD, 544 men and 315 women experienced a 40% decline in eGFR during a median follow-up of 26.4 months. Compared to Q1 of A Body Shape Index, Q3 and Q4 were associated with the kidney outcome in men, with adjusted hazard ratios and 95% confidence intervals of 1.32 (1.01–1.71) and 1.72 (1.34–2.21), respectively. The rate of eGFR decline over time was also greater in these categories in men. In contrast, the association between high values of A Body Shape Index and kidney outcomes did not reach statistical significance in women. High BMI was not associated with kidney outcomes in either sex. Conclusions: Higher values of A Body Shape Index were associated with CKD progression in older men in Japan, whereas this association was less evident in women.

  • Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease

    by Masaru Matsui, Masatoshi Nishimoto, Takaaki Kosugi, Shunsuke Kitamura, Aiko Oda, Masato Kawakami, Akiko Itano, Takayuki Uemura, Hiroyuki Tamaki, Hikari Tasaki, et al.

    Background: Despite treatment with renin–angiotensin system inhibitors (RASis) and sodium–glucose cotransporter 2 inhibitors (SGLT2is), diabetic kidney disease (DKD) continues to exhibit substantial residual renal risk. The renoprotective effects of adding finerenone to dual therapy remain incompletely characterised. Methods: A total of 255 patients with DKD receiving combined RASi and SGLT2i therapy were analysed by intention‐to‐treat as triple combination therapy (TCT) with finerenone or dual combination therapy (DCT) alone. The outcomes were longitudinal changes in proteinuria, serum potassium and estimated glomerular filtration rate (eGFR) slope, including total eGFR slope over 24 months and the post–initial dip eGFR slope from 3 to 24 months, evaluated before and after propensity score (PS) matching. Results: Over a 24‐month follow‐up period, TCT was associated with a greater and sustained reduction in proteinuria compared with DCT, with significant reductions of 47% at 24 months ( p = 0.028). Although the total eGFR slope did not differ significantly between groups, the post–initial dip slope was significantly improved in the TCT group, with an attenuation of annual eGFR decline by approximately 1.31 mL/min/1.73 m 2 /year (95% CI: 0.25 to 2.36) compared with DCT ( p = 0.015). After PS matching, this association remained significant (between‐group difference 1.45 mL/min/1.73 m 2 /year; 95% CI: 0.32–2.58; p = 0.012). Serum potassium increased modestly in the early phase of TCT but stabilised thereafter, with no significant difference between groups at 24 months. Conclusions: Among patients with DKD receiving RASi and SGLT2i therapy, the addition of finerenone was associated with greater proteinuria reduction and a significant improvement in the post–initial dip eGFR slope, suggesting that TCT may offer an additional renoprotective strategy in DKD.

  • Open Access

    SGLT2 inhibitors preserve serum chloride in non-diabetic CKD: a propensity-matched and LASSO regression analysis

    by Masaru Matsui, Takaaki Kosugi, Shunsuke Kitamura, Masatoshi Nishimoto, Akiko Itano, Marumi Yamamoto, Haruka Yabuta, Aiko Oda, Masato Kawakami, Hideo Tsushima, et al.

    Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel renoprotective agents for patients with chronic kidney disease (CKD) and have diverse effects, including on the regulation of electrolyte balance. However, their effects on serum chloride concentrations remain unclear. We conducted a retrospective single-center study of 343 CKD patients without diabetes or proteinuria who were not taking diuretics, including 202 SGLT2i users and 141 non-users, and applied propensity score (PS) matching and LASSO regression analysis. The outcomes were the change in chloride concentration with adjustment for covariates, before and after PS matching. Factors associated with these changes were identified using multivariable analysis and LASSO regression. An adjusted linear mixed effects model showed that the annual changes in chloride concentration for the non-SGLT2i and SGLT2i users were -0.39 (95% CI: -0.61 to 0.17) mEq/L/year and 0.49 (95% CI: -0.02 to 1.00) mEq/L/year, respectively [difference 0.88 (95% CI: 0.58 to 1.17) mEq/L/year] (p < 0.001). After PS matching, there was also a significant difference between users and non-users of SGLT2is in the mean change in chloride concentration [difference 0.44 (95% CI: 0.03 to 0.84) mEq/L/year] (p = 0.036). Subgroup analyses confirmed these findings. Furthermore, the use of SGLT2is had the strongest influence on the 2-year change in serum chloride concentration. To our knowledge, this is the first propensity-matched study to demonstrate a sustained chloride-preserving effect of SGLT2 inhibitors in non-diabetic CKD. In conclusion, this study identifies a previously underrecognized tubular electrolyte effect of SGLT2 inhibitors-preservation of serum chloride-which may partly explain their consistent cardioprotective effects across diverse CKD populations.


  • Open Access

    Association of Estimated Glomerular Filtration Rate Slopes with Cardiorenal Outcomes in Patients with Chronic Kidney Disease before and after Multidisciplinary Education

    by Masaru Matsui, Maiko Kokubu, Masatoshi Nishimoto, Takaaki Kosugi, Masahiro Eriguchi, Ken-Ichi Samejima, Kazuhiko Tsuruya

    Introduction: Multidisciplinary education has been shown to slow the progression of chronic kidney disease (CKD) and reduce cardiovascular (CV) risk, although its effects depend partly on patient characteristics. The aim of this study was to assess how patients categorized on the basis of estimated glomerular filtration rate (eGFR) responded to multidisciplinary education in terms of cardiorenal outcomes. Methods: In this retrospective cohort study, we included 447 CKD patients who received multidisciplinary education between January 1, 2013, and December 31, 2020, at Nara Prefecture General Medical Center. Exposure was four categories according to eGFR slopes before and after multidisciplinary education. The primary outcomes were renal events defined as the composite of dialysis initiation, transplantation, and 30% eGFR decline, and CV events defined as the composite of heart failure requiring hospitalization, coronary or leg revascularization, cardiac sudden death, and stroke. Results: Multidisciplinary education decreased the median eGFR slope from −5.00 to −0.65 mL/min/1.73 m2/year. In fully adjusted models, the hazard ratios (95% confidence intervals) for total renal events relative to slow-slow eGFR decline were 1.02 (0.50–2.06) for fast-slow decline, 5.30 (2.82–9.97) for slow-fast decline, and 7.53 (4.02–14.1) for fast-fast decline. Only fast-fast eGFR decline was associated with a high risk of CV events. Subgroup analyses showed similar trends. Fast decline after education was independently associated with increased proteinuria and decreased hemoglobin levels. Conclusions: Fast eGFR decline after but not before multidisciplinary education was significantly associated with renal and CV events in CKD patients. Attention should be paid to CKD patients with limited benefit from multidisciplinary education.


  • Open Access

    Design and rationale for a pilot trial of D-alanine supplementation to reduce the triglyceride to high-density lipoprotein cholesterol ratio in patients with chronic kidney disease

    by Masaru Matsui, Masatoshi Nishimoto, Takayuki Uemura, Shunsuke Kitamura, Wasako Tato, Hideo Tsushima, Takaaki Kosugi, Masahiro Eriguchi, Ken-Ichi Samejima, Masashi Mita, et al.

    Chronic kidney disease (CKD) is an increasingly prevalent disease that adversely affects patients’ quality of life and medical expenses. While its progression is linked to lifestyle-related diseases, its association with dyslipidemia remains unclear. We previously showed a significant association between a high triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio and CKD progression and cardiovascular disease in CKD patients. Recent reports indicate that D-alanine regulates circadian rhythms, participates in gluconeogenesis, and exhibits renoprotective effects. This study will investigate whether D-alanine has a beneficial effect on the TG/HDL-C ratio in CKD patients. This open-label, multicenter, single-arm, exploratory trial will involve 20 CKD patients and last for 10 weeks, including a 2-week run-in, 4-week treatment, and 4-week follow-up period. Patients will be recruited from Nara Medical University and Nara Prefectural General Medical Center. The primary endpoint is the change in fasting TG/HDL-C ratios between baseline and Day 28. Secondary endpoints include changes in fasting TG, HDL-C, low-density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, glycated hemoglobin A1c, systolic and diastolic blood pressure, proteinuria, estimated glomerular filtration rate, and body weight between baseline and Day 28. The study will summarize absolute measurements and changes using descriptive statistics, confidence intervals, and line graphs showing means ± confidence intervals. A two-tailed significance level of p < 0.05 will be used. This exploratory study aims to evaluate the efficacy and safety of D-alanine for treating dyslipidemia in CKD patients, and may provide insights that help reduce the risk of cardiorenal events in CKD patients. This protocol was approved by the Clinical Trial Review Board of Nara Medical University Clinical Research Review Committee (CRB5200002) on February 5, 2025, and is available to the public on the website of the Japan Registry of Clinical Trials on December 18, 2024 (jRCTs051240262).

  • Open Access

    Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Lower eGFR Decline in Nondiabetic CKD Patients without Proteinuria

    by Masaru Matsui, Takaaki Kosugi, Kosuke Tansho, Shunsuke Kitamura, Masatoshi Nishimoto, Keisuke Okamoto, Masahiro Eriguchi, Ken-Ichi Samejima, Kazuhiko Tsuruya

    Key Points: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) significantly slowed chronic decline in eGFR in nondiabetic CKD patients without proteinuria. Propensity score–matched analysis confirmed that SGLT2i users had a significantly slower postinitial dip eGFR slope than nonusers. Subgroup analyses consistently supported the renoprotective effect of SGLT2is in this population. Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown promise as renoprotective agents, building on the success of renin-angiotensin system blockers. Although SGLT2is have been shown to slow renal deterioration in diabetic and nondiabetic CKD with proteinuria, it is unclear whether similar effects occur in nondiabetic, nonproteinuric CKD. Methods: This study used propensity score analysis to evaluate the effects of SGLT2is on changes in annual eGFR in nondiabetic CKD patients with trivial proteinuria (urinary protein–creatinine ratio 2 , and median urinary protein–creatinine ratio of 0.15 (0.09–0.29) g/gCr. Results: Adjusted linear mixed-effects models showed that while the eGFR decline over a 3-year period (total) was similar between the two groups, there was a significantly smaller decline between 3 months after baseline and 2-year follow-up (chronic) in SGLT2i users compared with nonusers, with a difference of 1.23 (95% confidence interval, 0.43 to 2.02; P = 0.002) ml/min per 1.73 m 2 per year. After propensity score matching, SGLT2i users exhibited significantly slower chronic decline than nonusers, with a difference of 1.50 (95% confidence interval, 0.63 to 2.36; P < 0.001) ml/min per 1.73 m 2 per year. Subgroup analyses confirmed these findings. Conclusions: This study suggests that SGLT2is may slow eGFR decline in non-diabetic CKD patients with trivial proteinuria, supporting the potential use of SGLT2is as renoprotective agents in this population.


  • Open Access

    sFlt-1 in Chronic Kidney Disease: Friend or Foe?

    by Masaru Matsui, Kenji Onoue, Yoshihiko Saito

    Placental growth factor (PlGF) and its receptor, fms-like tyrosine kinase-1 (Flt-1), are important regulators involved in angiogenesis, atherogenesis, and inflammation. This review article focuses on the function of PlGF/Flt-1 signaling and its regulation by soluble Flt-1 (sFlt-1) in chronic kidney disease (CKD). Elevation of circulating sFlt-1 and downregulation of sFlt-1 in the vascular endothelium by uremic toxins and oxidative stress both exacerbate heart failure and atherosclerosis. Circulating sFlt-1 is inconsistent with sFlt-1 synthesis, because levels of matrix-bound sFlt-1 are much higher than those of circulating sFlt-1, as verified by a heparin loading test, and are drastically reduced in CKD.


  • Kidney function at 3 months after acute kidney injury is an unreliable indicator of subsequent kidney dysfunction: the NARA-AKI Cohort Study

    by Masatoshi Nishimoto, Miho Murashima, Maiko Kokubu, Masaru Matsui, Masahiro Eriguchi, Ken-Ichi Samejima, Yasuhiro Akai, Kazuhiko Tsuruya

    Background: The relationship between kidney function at 3 months after acute kidney injury (AKI) and kidney function prognosis has not been characterized.Methods: This retrospective cohort study included adults who underwent noncardiac surgery under general anesthesia. Exclusion criteria included obstetric or urological surgery, missing data and preoperative dialysis. Linear mixed-effects models were used to compare estimated glomerular filtration rate (eGFR) slopes in patients with and without AKI. Multivariable Cox proportional hazard models were used to examine the associations of AKI with incident chronic kidney disease (CKD) and decline in eGFR ≥30%.Results: Among 5272 patients, 316 (6.0%) developed AKI. Among 1194 patients with follow-up creatinine values, eGFR was stable or increased in patients with and without AKI at 3 months postoperatively and declined thereafter. eGFR decline after 3 months postoperatively was faster among patients with AKI than among patients without AKI (P = .09). Among 938 patients without CKD—both at baseline and at 3 months postoperatively—226 and 161 developed incident CKD and a decline in eGFR ≥30%, respectively. Despite adjustment for eGFR at 3 months, AKI was associated with incident CKD {hazard ratio [HR] 1.73 [95% confidence interval (CI) 1.06–2.84]} and a decline in eGFR ≥30% [HR 2.41 (95% CI 1.51–3.84)].Conclusions: AKI was associated with worse kidney outcomes, regardless of eGFR at 3 months after surgery. Creatinine-based eGFR values at 3 months after AKI might be affected by acute illness-induced loss of muscle mass. Kidney function might be more accurately evaluated much later after surgery or using cystatin C values.


  • Open Access

    Anemia following acute kidney injury after noncardiac surgery and long-term outcomes: the NARA-AKI cohort study

    by Masatoshi Nishimoto, Miho Murashima, Maiko Kokubu, Masaru Matsui, Masahiro Eriguchi, Ken-Ichi Samejima, Yasuhiro Akai, Kazuhiko Tsuruya

    This study was conducted to investigate whether acute kidney injury (AKI) is an independent predictor of anemia and whether anemia following AKI is a mediator of mortality after AKI. This is a retrospective cohort study. Adults with noncardiac surgery from 2007 to 2011 were included. Obstetric or urological surgery, missing data or preoperative dialysis were excluded. Subjects were followed until the end of 2015 or lost to follow-up. Exposures of interest were postoperative AKI. Outcome variables were hematocrit values at 3, 6 and 12 months postoperatively and mortality. Associations between AKI and hematocrit or association between AKI and mortality were examined by multivariable linear regression or Cox regression, respectively. Among 6692 subjects, 445 (6.6%) developed AKI. Among those with postoperative data, AKI was independently associated with lower hematocrit at 3, 6 and 12 months postoperatively, with coefficients of −0.79 [95% confidence interval (CI) −1.47 to −0.11; n = 1750], −1.35 (−2.11 to −0.60; n = 1558) and −0.91 (−1.59 to −0.22; n = 2463), respectively. Higher stages or longer duration of AKI were associated with more severe anemia. AKI was associated with higher mortality after 3 months postoperatively with a hazard ratio of 1.54 (95% CI 1.12–2.12). Further adjustment with hematocrit at 3 months attenuated the association. The mediation effect was significant (P = 0.02) by mediation analysis. AKI was an independent predictor of anemia following AKI. Higher mortality associated with AKI was at least partially mediated by anemia following AKI. Whether correction of anemia following AKI improves mortality requires further research.


  • Open Access

    Effect of Lomerizine Hydrochloride on Preventing Strokes in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy

    by Akiko Watanabe-Hosomi, Ikuko Mizuta, Takashi Koizumi, Isao Yokota, Mao Mukai, Ai Hamano, Masaki Kondo, Akihiro Fujii, Masaru Matsui, Koushun Matsuo, et al.

    Background Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an orphan disease clinically characterized by migraine, recurrent strokes, and dementia. Currently, there are no disease-modifying therapies, and it is difficult to prevent cerebral ischemic events in CADASIL patients by conventional antithrombotic medication. We hypothesized that an antimigraine agent, lomerizine hydrochloride, may prevent strokes in CADASIL patients, based on its effect on increasing cerebral blood flow. Subjects and Methods This was an open-labeled clinical trial in which 30 adult CADASIL patients received lomerizine at 10 mg/d. Numbers of symptomatic strokes during the 2 years after the start of lomerizine administration were compared with those in the 2 years before its initiation. The effect of lomerizine on preventing strokes was evaluated based on the incidence rate ratio (IR) calculated with the Mantel-Haenszel method. Results When including all 30 patients (analysis 1), the IR was less than 1 (0.46; 95% confidence interval [CI], 0.19–1.12) but did not reach significance. To evaluate the effect of lomerizine on secondary prevention, subgroups of 15 patients with stroke episodes occurring any time before lomerizine administration (analysis 2) and 10 patients with stroke episodes during the 2 years before lomerizine administration (analysis 3) were analyzed. The IR values were 0.33 (95% CI, 0.12–0.94) in analysis 2 and 0.17 (95% CI, 0.04–0.67) in analysis 3. Conclusions Our results suggest the effect of lomerizine on preventing secondary stroke in CADASIL patients.